Do analysts prefer COAG or AVTE?

Hemab Therapeutics presently has a consensus price target of $48.00, suggesting a potential upside of 1.57%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hemab Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, COAG or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$23.98 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is COAG or AVTE more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts rate AVTE or IOVA?

Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 79.33%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Iovance Biotherapeutics 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.30

Do analysts recommend BHVN or AVTE?

Biohaven presently has a consensus price target of $21.63, indicating a potential upside of 57.19%. Given Biohaven's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biohaven is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 2 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.67 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, BHVN or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is BHVN or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts rate AVTE or MLYS?

Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 83.06%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mineralys Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has preferable earnings & valuation, AVTE or MLYS?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is AVTE or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Mineralys Therapeutics N/A -27.92% -26.98%

Do analysts rate PHVS or AVTE?

Pharvaris presently has a consensus price target of $50.08, suggesting a potential upside of 48.84%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.79 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, PHVS or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is PHVS or AVTE more profitable?

Pharvaris' return on equity of -67.56% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Aerovate Therapeutics N/A -90.19% -77.47%

Aerovate Therapeutics (AVTE) Competitors

$19.95 -0.13 (-0.65%)

As of 07/27/2026

Compare

AVTE vs. COAG, IOVA, BHVN, MLYS, and PHVS

Should you buy Aerovate Therapeutics stock or one of its competitors? MarketBeat compares Aerovate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aerovate Therapeutics include Hemab Therapeutics (COAG), Iovance Biotherapeutics (IOVA), Biohaven (BHVN), Mineralys Therapeutics (MLYS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does Aerovate Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Aerovate Therapeutics (NASDAQ:AVTE) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Hemab Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Hemab Therapeutics presently has a consensus price target of $48.00, suggesting a potential upside of 1.57%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hemab Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hemab Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Hemab Therapeutics and 0 mentions for Aerovate Therapeutics. Hemab Therapeutics' average media sentiment score of 0.29 beat Aerovate Therapeutics' score of 0.00 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Hemab Therapeutics	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Hemab Therapeutics beats Aerovate Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Iovance Biotherapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 17 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 0 mentions for Aerovate Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.89 beat Aerovate Therapeutics' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Iovance Biotherapeutics	Positive

Aerovate Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Aerovate Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Iovance Biotherapeutics	$263.50M	7.96	-$390.98M	-$0.95	N/A

Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 79.33%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Iovance Biotherapeutics beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Aerovate Therapeutics' return on equity of -90.19% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

88.8% of Biohaven shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biohaven presently has a consensus price target of $21.63, indicating a potential upside of 57.19%. Given Biohaven's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biohaven is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Biohaven had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Biohaven and 0 mentions for Aerovate Therapeutics. Biohaven's average media sentiment score of 0.34 beat Aerovate Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the media.

Company	Overall Sentiment
Biohaven	Neutral
Aerovate Therapeutics	Neutral

Summary

Biohaven beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Mineralys Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 0 mentions for Aerovate Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.14 beat Aerovate Therapeutics' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Mineralys Therapeutics	Positive

Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 83.06%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics' return on equity of -27.92% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Summary

Mineralys Therapeutics beats Aerovate Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Pharvaris presently has a consensus price target of $50.08, suggesting a potential upside of 48.84%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pharvaris has a beta of -2.34, indicating that its share price is 334% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Pharvaris' return on equity of -67.56% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Pharvaris had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Pharvaris and 0 mentions for Aerovate Therapeutics. Pharvaris' average media sentiment score of 1.01 beat Aerovate Therapeutics' score of 0.00 indicating that Pharvaris is being referred to more favorably in the media.

Company	Overall Sentiment
Pharvaris	Positive
Aerovate Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Pharvaris beats Aerovate Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTE vs. The Competition

Export

Metric	Aerovate Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$578.25M	$945.02M	$7.04B	$12.13B
Dividend Yield	N/A	4.84%	2.67%	9.43%
P/E Ratio	-6.67	1.52	27.30	23.79
Price / Sales	N/A	103.71	510.90	89.25
Price / Cash	N/A	22.05	26.39	46.66
Price / Book	5.04	8.58	10.27	6.10
Net Income	-$75.52M	-$3.26M	$3.60B	$336.45M
7 Day Performance	1.42%	-0.36%	-1.79%	-2.14%
1 Month Performance	-9.32%	-6.22%	-2.66%	-3.31%
1 Year Performance	140.94%	26.14%	18.22%	13.49%

Aerovate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTE Aerovate Therapeutics	N/A	$19.95 -0.6%	N/A	+142.5%	$578.25M	N/A	N/A	20	High Trading Volume
COAG Hemab Therapeutics	1.7281 of 5 stars	$48.28 -2.2%	$48.00 -0.6%	N/A	$2.25B	N/A	N/A	72
IOVA Iovance Biotherapeutics	2.7279 of 5 stars	$5.48 +9.2%	$8.43 +53.8%	+56.5%	$2.24B	$263.50M	N/A	500	News Coverage Analyst Revision
BHVN Biohaven	3.3901 of 5 stars	$15.52 +4.4%	$21.63 +39.3%	+7.4%	$2.24B	N/A	N/A	239
MLYS Mineralys Therapeutics	3.8073 of 5 stars	$27.52 +3.0%	$49.33 +79.3%	+90.0%	$2.20B	N/A	N/A	28	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. COAG, IOVA, BHVN, MLYS, and PHVS

How does Aerovate Therapeutics compare to Hemab Therapeutics?

Summary

How does Aerovate Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Aerovate Therapeutics compare to Biohaven?

Summary

How does Aerovate Therapeutics compare to Mineralys Therapeutics?

Summary

How does Aerovate Therapeutics compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. COAG, IOVA, BHVN, MLYS, and PHVS

How does Aerovate Therapeutics compare to Hemab Therapeutics?

Is COAG or AVTE more profitable?

Do analysts prefer COAG or AVTE?

Does the media refer more to COAG or AVTE?

Which has better valuation & earnings, COAG or AVTE?

Summary

How does Aerovate Therapeutics compare to Iovance Biotherapeutics?

Which has more risk & volatility, AVTE or IOVA?

Does the media favor AVTE or IOVA?

Is AVTE or IOVA more profitable?

Which has stronger valuation & earnings, AVTE or IOVA?

Do analysts rate AVTE or IOVA?

Do institutionals and insiders hold more shares of AVTE or IOVA?

Summary

How does Aerovate Therapeutics compare to Biohaven?

Is BHVN or AVTE more profitable?

Which has better earnings & valuation, BHVN or AVTE?

Do institutionals and insiders believe in BHVN or AVTE?

Do analysts recommend BHVN or AVTE?

Which has more volatility & risk, BHVN or AVTE?

Does the media refer more to BHVN or AVTE?

Summary

How does Aerovate Therapeutics compare to Mineralys Therapeutics?

Do institutionals & insiders believe in AVTE or MLYS?

Which has preferable earnings & valuation, AVTE or MLYS?

Does the media refer more to AVTE or MLYS?

Which has more risk & volatility, AVTE or MLYS?

Do analysts rate AVTE or MLYS?

Is AVTE or MLYS more profitable?

Summary

How does Aerovate Therapeutics compare to Pharvaris?

Do analysts rate PHVS or AVTE?

Which has more volatility & risk, PHVS or AVTE?

Is PHVS or AVTE more profitable?

Does the media favor PHVS or AVTE?

Which has stronger valuation & earnings, PHVS or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools